Celularity Inc
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $26.6M | $54.2M | $22.8M | $18.0M | $21.3M |
| Cost of revenue | $20.1M | $15.0M | $16.0M | — | — |
| Gross profit | — | — | $6.8M | -$1.7M | $11.7M |
| Selling, general & administrative | $51.3M | $58.6M | $50.6M | $66.0M | $71.3M |
| Research and development | $15.0M | $17.4M | $30.5M | $78.4M | $88.4M |
| Operating income | -$61.3M | -$38.4M | -$192.3M | -$25.6M | -$109.1M |
| Pretax income | -$91.7M | -$57.9M | -$196.3M | $14.2M | -$100.1M |
| Income tax expense | $3,000 | — | $10,000 | $13,000 | $20,000 |
| Net income | -$91.7M | -$57.9M | -$196.3M | $14.2M | -$100.1M |
| Balance Sheet | |||||
| Cash and equivalents | $6.2M | $738,000 | $227,000 | $14.0M | $37.2M |
| Current assets | $12.3M | $20.6M | $19.8M | $33.5M | $59.1M |
| Total assets | $107.3M | $132.7M | $143.9M | $401.1M | $414.1M |
| Current liabilities | $80.8M | $53.7M | $67.3M | $62.1M | $26.2M |
| Total liabilities | $145.4M | $123.8M | $102.9M | $202.2M | $314.7M |
| Stockholders' equity | -$38.1M | $8.8M | $41.0M | $198.9M | $99.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$13.3M | -$6.4M | -$38.7M | -$137.9M | -$110.1M |
| Depreciation and amortization | $7.3M | $7.9M | $9.3M | $9.4M | $8.8M |
| Stock-based compensation | $10.6M | $11.6M | $0 | $15.9M | $40.0M |
| Capital expenditure | — | $161,000 | $1.0M | $5.2M | $6.2M |
| Free cash flow | — | -$6.6M | -$39.7M | -$143.1M | -$116.3M |
| Share repurchases | — | — | — | $86,000 | — |
| Impairments | $0 | $0 | $112.3M | $3.6M | $0 |
Shares outstanding 28.3M
Annual filing data through FY ended December 31, 2025; float as of July 4, 2026.